Table of Content



1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Chemotherapy Induced Peripheral Neuropathy Treatment
1.2 Key Market Segments
1.2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
1.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats

2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
2.1 Global Market Overview
2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) Estimates and Forecasts (2017-2028)
2.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts (2017-2028)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (2017-2022)
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Manufacturers (2017-2022)
3.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Manufacturers (2017-2022)
3.5 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Sales Sites, Area Served, Product Type
3.6 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Situation and Trends
3.6.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Rate
3.6.2 Global 5 and 10 Largest Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion

4 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain Analysis
4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain Analysis
4.2 Market Overview and Market Concentration Analysis of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 The Development and Dynamics of Chemotherapy Induced Peripheral Neuropathy Treatment Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies

6 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2017-2022)
6.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Market Share by Type (2017-2022)
6.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2017-2022)

7 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Sales by Application (2017-2022)
7.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) by Application (2017-2022)
7.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2017-2022)

8 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Region
8.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region
8.2 North America
8.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa

9 Key Companies Profiled
9.1 Aptinyx Inc
9.1.1 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.1.2 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.1.4 Aptinyx Inc Business Overview
9.1.5 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.1.6 Aptinyx Inc Recent Developments
9.2 Asahi Kasei Pharma Corp
9.2.1 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.2.2 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.2.4 Asahi Kasei Pharma Corp Business Overview
9.2.5 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.2.6 Asahi Kasei Pharma Corp Recent Developments
9.3 Regenacy Pharmaceuticals
9.3.1 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.3.2 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.3.4 Regenacy Pharmaceuticals Business Overview
9.3.5 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.3.6 Regenacy Pharmaceuticals Recent Developments
9.4 MAKScientific LLC
9.4.1 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.4.2 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.4.4 MAKScientific LLC Business Overview
9.4.5 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.4.6 MAKScientific LLC Recent Developments
9.5 Metys Pharmaceuticals AG
9.5.1 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.5.2 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.5.4 Metys Pharmaceuticals AG Business Overview
9.5.5 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.5.6 Metys Pharmaceuticals AG Recent Developments
9.6 Nemus Bioscience Inc
9.6.1 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.6.2 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.6.4 Nemus Bioscience Inc Business Overview
9.6.5 Nemus Bioscience Inc Recent Developments
9.7 PledPharma
9.7.1 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.7.2 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.7.4 PledPharma Business Overview
9.7.5 PledPharma Recent Developments
9.8 Sova Pharmaceuticals Inc
9.8.1 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.8.2 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.8.4 Sova Pharmaceuticals Inc Business Overview
9.8.5 Sova Pharmaceuticals Inc Recent Developments
9.9 DermaXon LLC
9.9.1 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.9.2 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.9.4 DermaXon LLC Business Overview
9.9.5 DermaXon LLC Recent Developments
9.10 Kineta Inc
9.10.1 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.10.2 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.10.4 Kineta Inc Business Overview
9.10.5 Kineta Inc Recent Developments
9.11 Krenitsky Pharmaceuticals Inc
9.11.1 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.11.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.11.4 Krenitsky Pharmaceuticals Inc Business Overview
9.11.5 Krenitsky Pharmaceuticals Inc Recent Developments
9.12 PeriphaGen
9.12.1 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.12.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.12.4 PeriphaGen Business Overview
9.12.5 PeriphaGen Recent Developments
9.13 Apexian Pharma
9.13.1 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.13.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.13.4 Apexian Pharma Business Overview
9.13.5 Apexian Pharma Recent Developments
9.14 WinSanTor
9.14.1 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.14.2 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.14.4 WinSanTor Business Overview
9.14.5 WinSanTor Recent Developments

10 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Region
10.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast
10.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country
10.2.3 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Region
10.2.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Chemotherapy Induced Peripheral Neuropathy Treatment by Country

11 Forecast Market by Type and by Application (2022-2028)
11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Type (2022-2028)
11.1.1 Global Forecasted Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2022-2028)
11.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Type (2022-2028)
11.1.3 Global Forecasted Price of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2022-2028)
11.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Application (2022-2028)
11.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Forecast by Application
11.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) Forecast by Application (2022-2028)

12 Conclusion and Key Findings



List of Figures

?LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) Comparison by Region (M USD)

Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Manufacturers (2017-2022)

Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers (2017-2022)

Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) by Manufacturers (2017-2022)

Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2017-2022)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2021)

Table 10. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (USD/Unit) of Key Manufacturers (2017-2022)

Table 11. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Sales Sites and Area Served

Table 12. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type

Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Chemotherapy Induced Peripheral Neuropathy Treatment

Table 16. Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges

Table 22. Market Restraints

Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (K Units)

Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (M USD)

Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2017-2022)

Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2017-2022)

Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) by Type (2017-2022)

Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Share by Type (2017-2022)

Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (USD/Unit) by Type (2017-2022)

Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application

Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application

Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2022) & (K Units)

Table 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2017-2022)

Table 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2022) & (M USD)

Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application (2017-2022)

Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2017-2022)

Table 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2017-2022) & (K Units)

Table 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2017-2022)

Table 39. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2017-2022) & (K Units)

Table 40. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2017-2022) & (K Units)

Table 41. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2017-2022) & (K Units)

Table 42. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2017-2022) & (K Units)

Table 43. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2017-2022) & (K Units)

Table 44. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 45. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 46. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 47. Aptinyx Inc Business Overview

Table 48. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis

Table 49. Aptinyx Inc Recent Developments

Table 50. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 51. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 52. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 53. Asahi Kasei Pharma Corp Business Overview

Table 54. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis

Table 55. Asahi Kasei Pharma Corp Recent Developments

Table 56. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 57. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 58. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 59. Regenacy Pharmaceuticals Business Overview

Table 60. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis

Table 61. Regenacy Pharmaceuticals Recent Developments

Table 62. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 63. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 64. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 65. MAKScientific LLC Business Overview

Table 66. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis

Table 67. MAKScientific LLC Recent Developments

Table 68. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 69. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 70. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 71. Metys Pharmaceuticals AG Business Overview

Table 72. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis

Table 73. Metys Pharmaceuticals AG Recent Developments

Table 74. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 75. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 76. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 77. Nemus Bioscience Inc Business Overview

Table 78. Nemus Bioscience Inc Recent Developments

Table 79. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 80. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 81. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 82. PledPharma Business Overview

Table 83. PledPharma Recent Developments

Table 84. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 85. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 86. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 87. Sova Pharmaceuticals Inc Business Overview

Table 88. Sova Pharmaceuticals Inc Recent Developments

Table 89. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 90. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 91. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 92. DermaXon LLC Business Overview

Table 93. DermaXon LLC Recent Developments

Table 94. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 95. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 96. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 97. Kineta Inc Business Overview

Table 98. Kineta Inc Recent Developments

Table 99. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 100. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 101. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 102. Krenitsky Pharmaceuticals Inc Business Overview

Table 103. Krenitsky Pharmaceuticals Inc Recent Developments

Table 104. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 105. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 106. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 107. PeriphaGen Business Overview

Table 108. PeriphaGen Recent Developments

Table 109. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 110. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 111. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 112. Apexian Pharma Business Overview

Table 113. Apexian Pharma Recent Developments

Table 114. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information

Table 115. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview

Table 116. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)

Table 117. WinSanTor Business Overview

Table 118. WinSanTor Recent Developments

Table 119. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Region (K Units)

Table 120. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Region (M USD)

Table 121. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2022-2028) & (K Units)

Table 122. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2022-2028) & (M USD)

Table 123. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2022-2028) & (K Units)

Table 124. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2022-2028) & (M USD)

Table 125. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Region (2022-2028) & (K Units)

Table 126. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Region (2022-2028) & (M USD)

Table 127. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2022-2028) & (K Units)

Table 128. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2022-2028) & (M USD)

Table 129. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast by Country (2022-2028) & (Units)

Table 130. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2022-2028) & (M USD)

Table 131. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2022-2028) & (K Units)

Table 132. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Type (2022-2028) & (M USD)

Table 133. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Type (2022-2028) & (USD/Unit)

Table 134. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Forecast by Application (2022-2028)

Table 135. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Application

(2022-2028) & (M USD)

List of Figures

Figure 1. Product Picture of Chemotherapy Induced Peripheral Neuropathy Treatment

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD), 2017-2028

Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) (2017-2028)

Figure 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) & (2017-2028)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) by Country (M USD)

Figure 11. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturers in 2020

Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers in 2020

Figure 13. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021

Figure 14. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (USD/Unit) of Key Manufacturers in 2020

Figure 15. The Global 5 and 10 Largest Players: Market Share by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2021

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type

Figure 18. Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2017-2022)

Figure 19. Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type in 2021

Figure 20. Market Size Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2017-2022)

Figure 21. Market Size Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type in 2020

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application

Figure 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2017-2022)

Figure 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2021

Figure 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application (2017-2022)

Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application in 2020

Figure 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2017-2022)

Figure 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2017-2022)

Figure 30. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 31. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2020

Figure 32. U.S. Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 33. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) and Growth Rate (2017-2022)

Figure 34. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Units) and Growth Rate (2017-2022)

Figure 35. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 36. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2020

Figure 37. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 38. France Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 39. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 40. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 41. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 42. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region in 2020

Figure 44. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 45. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 46. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 47. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 48. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 49. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (K Units)

Figure 50. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2020

Figure 51. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 52. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 53. Columbia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 54. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region in 2020

Figure 56. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) &

(K Units)

Figure 57. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 58. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 59. Nigeria Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 60. South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2017-2022) & (K Units)

Figure 61. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Volume (2017-2028) & (K Units)

Figure 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Value (2017-2028) & (M USD)

Figure 63. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Type (2022-2028)

Figure 64. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Type (2022-2028)

Figure 65. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2022-2028)

Figure 66. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Application (2022-2028)